https://ezvetmobileservices.com/
For over 40 years, we have been serving the pets and families of South Florida. We love caring and connecting with animals and creating everlasting relationships. We provide veterinary care for your fur baby as if they were our own, and ensure that they receive the highest quality attention, from annual vaccines to acute care without leaving your home.
Blood cancers are the third leading cause of cancer deaths in the U.S. However, many Americans are unaware of the impact of these cancers, including leukemia, lymphoma and myeloma, which affect the bone marrow, the blood cells, the lymph nodes and other parts of the lymphatic system.
A new survey commissioned by The Leukemia & Lymphoma Society (LLS) reveals more than four in five adults (82%) are surprised that blood cancers are the third leading cancer killer of Americans. Further, nearly four in five adults (78%) are surprised that acute lymphocytic leukemia (ALL) is the most common cancer in children and young adults under age 20.
To view the multimedia release go to:
https://www.multivu.com/players/English/8128551-lls-blood-cancer-awareness-month/
Varian Medical Systems (NYSE: VAR) today is introducing the Halcyon™ system, an entirely new device for cancer treatment. Engineered to revolutionize clinical workflow, Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT). This new treatment system is designed to expand the availability of high quality cancer care globally and help save the lives of millions more cancer patients.
“The global cancer challenge is enormous,” said Kolleen Kennedy, president of Varian's Oncology Systems business. “It is expected that there will be 24.6 million cancer cases diagnosed annually by 2030, and there is an acute shortage of equipment and trained clinicians. With the innovations in this new technology platform, the system will deliver high quality Halcyon treatments that empower clinicians to care for many more patients. At Varian we are very excited with the introduction of Halcyon to be taking another big step toward advancing cost-effective cancer care worldwide.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8065951-varian-medical-systems-halcyon-cancer-treatment/
Going on the offensive against one of the most daunting challenges in cancer, The Leukemia & Lymphoma Society (LLS) today announced the launch of a groundbreaking, collaborative clinical trial for acute myeloid leukemia (AML), a deadly disease which has seen few improvements in treatments in more than 40 years.
Beat AML was announced yesterday by Vice President Biden, along with many new, Moonshot inspired initiatives across industry, non-profit and government.
AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more than 10,000 deaths each year. Despite advances in treating other blood cancers, the standard of treatment for AML – a combination of toxic chemotherapies – has remained the same for more than 40 years. Overall prognosis remains poor, with a five-year survival rate below 20 percent for patients over age 60.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554854-lls-beat-aml-acute-myeloid-leukemia/
Northwestern Mutual, presenting sponsor of the Rose Bowl Game, today announced that its float in the 127th Rose Parade presented by Honda in Pasadena on Jan. 1, 2016, will support the fight against childhood cancer.
The theme of this year’s parade is Find Your Adventure. Northwestern Mutual will dedicate its float design to the greatest adventure and dream of 13-year-old Peyton Richardson of Sugar Land, Texas, who is in treatment for acute lymphocytic leukemia (ALL). Northwestern Mutual is committed to raising awareness, accelerating the search for cures to childhood cancer and providing support to families battling the disease.
Peyton, an aspiring ballerina, would like to see the performances of the distinguished ballet companies of the world and have a ballet lesson with one of their principal dancers. Peyton’s adventure will be brought to life in flowers by Fiesta Parade Floats.
To view the multimedia release go to:
http://www.multivu.com/players/English/7422154-northwestern-mutual-rose-bowl/
Findings from continued clinical studies of investigational chimeric antigen receptor (CAR) therapy, CTL019, demonstrate its potential role in the treatment of certain types of lymphocytic leukemia. In one long-term study of pediatric patients with acute lymphoblastic leukemia (ALL), results showed that 36 of 39 pediatric patients with relapsed/refractory (r/r) ALL, or 92%, experienced complete remissions (CR) with CTL0191.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7393851-novartis-new-ctl019-clinic-data-acute-lymphoblastic-leukemia/
Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient’s immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children’s Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64394-chop-penn-harness-engineered-t-cells-eliminate-tumors-in-blood-leukemia
In this video Annabel Fisher talks about how the highly sensitive person often suffers pain because of the acute awareness all around them. Annabel shows how with EFT Tapping that painful feeling can be turned out to an acceptance of self and the gift of being highly sensitive as a blessing.
Research led by the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project has identified a fusion gene responsible for almost 30 percent of a rare subtype of childhood leukemia with an extremely poor prognosis.
The finding offers the first evidence of a mistake that gives rise to a significant percentage of acute megakaryoblastic leukemia (AMKL) cases in children. AMKL accounts for about 10 percent of pediatric acute myeloid leukemia (AML). The discovery paves the way for desperately needed treatment advances.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58586-st-jude-children-s-research-hospital-gene-sequencing-childhood-leukemia
Janssen Healthcare Innovation, a team within Janssen Research & Development, LLC (Janssen), today announced Discharge Decision Support System (D2S2) is the winner of the crowdsourcing-inspired Janssen Connected Care Challenge and the $100,000 prize. D2S2 is a discharge decision support system that uses a proprietary algorithm to assemble and score key data upon hospital admission in order to identify patients who should be referred to post-acute care services to reduce the risk of 30-day readmissions.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56342-discharge-decision-support-system-janssen-connected-care-challenge
New recommendations from the American Society of Clinical Rheumatologists (ASCR), published in Postgraduate Medicine, highlight updated management recommendations for patients with acute gout. These new recommendations come at a time when the incidence of gout is soaring; 8.3 million Americans are estimated to be gout patients.
Instead of challenging, restrictive dieting, patients are encouraged to consume a balanced diet of fresh fruit and vegetables, low-fat dairy products, nuts and grains. More importantly, patients should limit their intake of high fructose corn syrup, a common ingredient in many processed foods and drinks, and purine-rich foods, particularly red meat, beer and shellfish.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56234-gout-uric-acid-education-arthritis-lifestyle-change-treatment-options
Today the International OCD Foundation (IOCDF), announced their support for children and families suffering from Sudden Onset Obsessive Compulsive Disorder. They are releasing two new PSAs created to bring awareness and engender change surrounding the disorder PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections) and PANS (Pediatric Acute-Onset Neuropsychiatric Syndrome).
To view Multimedia News Release, go to http://www.multivu.com/mnr/54781-ocd-foundation-pandas-psa-obsessive-compulsive-disorder
